Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company is projected to generate revenue of 2.649 billion RMB in 2025, representing a decline of 5.8% year-over-year, with adjusted net profit expected to be 209 million RMB, down 49.7% year-over-year. The decline is attributed to an increase in the proportion of artificial insemination (IUI) affecting the number of egg retrieval cycles and pricing, along with zero markup on drug costs. However, there is a significant improvement expected in the second half of the year [1][5] - For 2026, the outlook is positive, driven by the implementation of the California commercial insurance law SB729, which is expected to catalyze a 38% year-over-year increase in cycle numbers in January and February. The new facility in Shenzhen is also expected to contribute positively, with a projected 18% year-over-year increase in cycle numbers [1][2] Summary by Sections Domestic Business - The revenue in the Greater Bay Area is expected to decline by 8.8% to 420 million RMB in 2025, primarily due to a higher proportion of lower-cost IUI cycles and delays in the relocation of the Shenzhen facility. However, a double-digit year-over-year growth is anticipated for the Shenzhen region in 2026, supported by a significant increase in capacity and higher customer pricing through premium services [2][3] Overseas Business - The HRC Fertility business in the U.S. is expected to benefit from the acceleration of commercial insurance coverage, with a projected revenue increase of 5.1% year-over-year in 2025. The implementation of SB729 is expected to enhance cycle numbers significantly, with a 38% year-over-year increase in January and February [3][4] Financial Forecast and Valuation - The company is expected to achieve adjusted EPS of 0.11 RMB in 2026, with a target price set at 3.25 HKD, reflecting a 26x PE ratio. This valuation considers the potential positive impact of the U.S. insurance coverage on revenue and pricing strategies [5][11]

Group 1 - The new national medical insurance drug list includes over 100 rare disease medications, covering more than 50 disease types, providing hope for more patients [1][3] - The drug Lenvatinib, approved for Langerhans cell histiocytosis, has a high monthly treatment cost of approximately 17,000 yuan, making it unaffordable for most patients [1][3] - The inclusion of Lenvatinib in the insurance list not only treats Langerhans cell histiocytosis but also extends to pediatric patients with neurofibromatosis type I, lowering the age limit for treatment from 3 years to 2 years [3][4] Group 2 - The national medical insurance has included 19 innovative drugs, including 6 rare disease medications, in a new commercial insurance model to improve accessibility [4] - Measures such as the publication of clinical guidelines for 86 rare disease types and the establishment of a national rare disease diagnosis and treatment collaboration network are being implemented to enhance patient care [4][5] - The combination of policy support and community initiatives, such as the "Little Cat Cheer Up" app for parents of rare disease children, is fostering a supportive environment for patients [4][5]

Group 1 - The new national medical insurance drug list includes over 100 rare disease medications, covering more than 50 disease types, providing hope for more patients [1] - The inclusion of the drug Lenvatinib for Langerhans cell histiocytosis in the insurance list is significant, as it also treats neurofibromatosis type I in children aged 2 and above, expanding access compared to previous coverage [1] - Currently, the insurance covers over 50 rare disease types, but there is still a gap compared to the 207 rare diseases listed, due to some diseases lacking effective treatments and the high costs of certain medications [1] Group 2 - The introduction of commercial insurance for innovative drug coverage includes 19 drugs, such as the expensive medication for neuroblastoma, which previously cost hundreds of thousands of yuan per treatment [2] - The measures taken, including the establishment of diagnostic guidelines for 86 rare diseases and a green channel for drug review and approval, aim to strengthen life protection for rare disease patients [2] - A small program created by a parent of a rare disease patient has facilitated communication among over 5,800 families, showcasing community support and shared experiences [2]

Market Overview - Major indices in China opened slightly lower, with the Shanghai Composite Index down 0.09%, the Shenzhen Component down 0.09%, and the ChiNext Index down 0.09% [1] - The Shanghai Composite Index closed at 3996.51, with a trading volume of 63.67 billion [2] - The Shenzhen Component Index closed at 13228.50, with a trading volume of 92.07 billion [2] - The NASDAQ Golden Dragon China Index fell by 1.46%, with notable declines in companies like Xpeng, NIO, and Baidu, which dropped over 2% [3] Industry Insights - CITIC Securities forecasts that the pharmaceutical industry will continue to be an overweight sector, driven by innovation and supportive policies, leading to stable growth in the domestic market [4] - China Galaxy Securities reports that the machinery industry has shown steady revenue growth, with total revenue reaching 18924 billion, a year-on-year increase of 8.43% [5] - Huatai Securities expresses optimism for the power grid equipment sector, highlighting a 47% and 44% increase in the unit price of new standard electric meters and transformers, respectively, indicating a recovery in profitability [6]

Core Insights - The report from CITIC Securities indicates a positive outlook for the pharmaceutical investment trend by 2026, driven by both domestic innovation and supportive policies [1] - The healthcare industry is expected to gradually return to a market pricing system based on clinical value and demand, leading to a stable domestic pharmaceutical market environment [1] - Listed companies in the pharmaceutical sector are anticipated to experience continuous and stable performance growth, contributing to the industry's growth certainty [1] Summary by Categories Investment Trends - The pharmaceutical industry is projected to maintain an overweight status, with a focus on innovation-driven and internationalization strategies [1] - Key investment themes for 2026 include: 1) Innovation-driven and internationalization, 2) Self-sufficiency, 3) Beneficiaries of policy changes such as optimized procurement and healthcare payment reforms [1] Market Environment - The internal and external catalysts for the healthcare industry are expected to persist, fostering a long-term development trend characterized by stability and growth [1] - The emphasis on clinical value and demand in pricing is likely to enhance the overall market environment for pharmaceuticals [1]